CorMedix (CRMD) Competitors

$7.92 +0.37 (+4.83%)

As of 01:33 PM Eastern

CRMD vs. HCM, ZLAB, ADPT, TRVI, and SION

Should you buy CorMedix stock or one of its competitors? MarketBeat compares CorMedix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CorMedix include HUTCHMED (HCM), Zai Lab (ZLAB), Adaptive Biotechnologies (ADPT), Trevi Therapeutics (TRVI), and Sionna Therapeutics (SION). These companies are all part of the "pharmaceutical products" industry.

How does CorMedix compare to HUTCHMED?

HUTCHMED (NASDAQ:HCM) and CorMedix (NASDAQ:CRMD) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

HUTCHMED currently has a consensus target price of $16.88, indicating a potential upside of 39.75%. CorMedix has a consensus target price of $15.00, indicating a potential upside of 89.51%. Given CorMedix's stronger consensus rating and higher possible upside, analysts clearly believe CorMedix is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
CorMedix	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

CorMedix has a net margin of 45.25% compared to HUTCHMED's net margin of 0.00%. CorMedix's return on equity of 45.57% beat HUTCHMED's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
CorMedix	45.25%	45.57%	24.76%

HUTCHMED has higher revenue and earnings than CorMedix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$548.51M	3.84	$456.91M	N/A	N/A
CorMedix	$311.71M	1.99	$163.05M	$2.13	3.72

8.8% of HUTCHMED shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by company insiders. Comparatively, 3.5% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

HUTCHMED has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, CorMedix has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market.

In the previous week, CorMedix had 19 more articles in the media than HUTCHMED. MarketBeat recorded 22 mentions for CorMedix and 3 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.93 beat CorMedix's score of 0.82 indicating that HUTCHMED is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HUTCHMED	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CorMedix	6 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CorMedix beats HUTCHMED on 9 of the 15 factors compared between the two stocks.

How does CorMedix compare to Zai Lab?

CorMedix (NASDAQ:CRMD) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

CorMedix presently has a consensus target price of $15.00, suggesting a potential upside of 89.51%. Zai Lab has a consensus target price of $45.83, suggesting a potential upside of 141.98%. Given Zai Lab's higher probable upside, analysts clearly believe Zai Lab is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Zai Lab	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.63

CorMedix has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	1.99	$163.05M	$2.13	3.72
Zai Lab	$460.16M	4.67	-$175.54M	-$1.62	N/A

In the previous week, CorMedix had 15 more articles in the media than Zai Lab. MarketBeat recorded 22 mentions for CorMedix and 7 mentions for Zai Lab. CorMedix's average media sentiment score of 0.82 beat Zai Lab's score of 0.18 indicating that CorMedix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	6 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

CorMedix has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market. Comparatively, Zai Lab has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

34.2% of CorMedix shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 3.5% of CorMedix shares are held by company insiders. Comparatively, 4.9% of Zai Lab shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

CorMedix has a net margin of 45.25% compared to Zai Lab's net margin of -39.29%. CorMedix's return on equity of 45.57% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
Zai Lab	-39.29%	-24.32%	-15.52%

Summary

CorMedix beats Zai Lab on 10 of the 16 factors compared between the two stocks.

How does CorMedix compare to Adaptive Biotechnologies?

Adaptive Biotechnologies (NASDAQ:ADPT) and CorMedix (NASDAQ:CRMD) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

CorMedix has a net margin of 45.25% compared to Adaptive Biotechnologies' net margin of -16.82%. CorMedix's return on equity of 45.57% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%
CorMedix	45.25%	45.57%	24.76%

Adaptive Biotechnologies currently has a consensus target price of $19.57, suggesting a potential upside of 54.43%. CorMedix has a consensus target price of $15.00, suggesting a potential upside of 89.51%. Given CorMedix's higher possible upside, analysts plainly believe CorMedix is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
CorMedix	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Adaptive Biotechnologies has a beta of 2.16, meaning that its stock price is 116% more volatile than the broader market. Comparatively, CorMedix has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market.

In the previous week, CorMedix had 15 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 22 mentions for CorMedix and 7 mentions for Adaptive Biotechnologies. CorMedix's average media sentiment score of 0.82 beat Adaptive Biotechnologies' score of 0.41 indicating that CorMedix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
CorMedix	6 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CorMedix has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	7.32	-$59.50M	-$0.33	N/A
CorMedix	$311.71M	1.99	$163.05M	$2.13	3.72

99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 34.2% of CorMedix shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 3.5% of CorMedix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

CorMedix beats Adaptive Biotechnologies on 10 of the 14 factors compared between the two stocks.

How does CorMedix compare to Trevi Therapeutics?

CorMedix (NASDAQ:CRMD) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

CorMedix has a net margin of 45.25% compared to Trevi Therapeutics' net margin of 0.00%. CorMedix's return on equity of 45.57% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
Trevi Therapeutics	N/A	-24.53%	-23.37%

CorMedix presently has a consensus price target of $15.00, indicating a potential upside of 89.51%. Trevi Therapeutics has a consensus price target of $22.90, indicating a potential upside of 69.82%. Given CorMedix's higher possible upside, equities research analysts clearly believe CorMedix is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

34.2% of CorMedix shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 3.5% of CorMedix shares are owned by company insiders. Comparatively, 18.3% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

CorMedix has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	1.99	$163.05M	$2.13	3.72
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A

In the previous week, CorMedix had 18 more articles in the media than Trevi Therapeutics. MarketBeat recorded 22 mentions for CorMedix and 4 mentions for Trevi Therapeutics. CorMedix's average media sentiment score of 0.82 beat Trevi Therapeutics' score of 0.68 indicating that CorMedix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	6 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trevi Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CorMedix has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market.

Summary

CorMedix beats Trevi Therapeutics on 11 of the 16 factors compared between the two stocks.

How does CorMedix compare to Sionna Therapeutics?

CorMedix (NASDAQ:CRMD) and Sionna Therapeutics (NASDAQ:SION) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

34.2% of CorMedix shares are held by institutional investors. 3.5% of CorMedix shares are held by company insiders. Comparatively, 3.9% of Sionna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

CorMedix has a net margin of 45.25% compared to Sionna Therapeutics' net margin of 0.00%. CorMedix's return on equity of 45.57% beat Sionna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
Sionna Therapeutics	N/A	-27.31%	-25.88%

CorMedix currently has a consensus price target of $15.00, suggesting a potential upside of 89.51%. Sionna Therapeutics has a consensus price target of $53.22, suggesting a potential upside of 35.13%. Given CorMedix's higher probable upside, analysts clearly believe CorMedix is more favorable than Sionna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Sionna Therapeutics	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.91

CorMedix has higher revenue and earnings than Sionna Therapeutics. Sionna Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	1.99	$163.05M	$2.13	3.72
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A

CorMedix has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market.

In the previous week, Sionna Therapeutics had 7 more articles in the media than CorMedix. MarketBeat recorded 29 mentions for Sionna Therapeutics and 22 mentions for CorMedix. CorMedix's average media sentiment score of 0.82 beat Sionna Therapeutics' score of -0.07 indicating that CorMedix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	6 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sionna Therapeutics	4 Very Positive mention(s)	6 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

CorMedix beats Sionna Therapeutics on 11 of the 15 factors compared between the two stocks.

Get CorMedix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRMD vs. The Competition

Export

Metric	CorMedix	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$623.29M	$3.27B	$6.23B	$12.21B
Dividend Yield	N/A	2.34%	2.81%	5.30%
P/E Ratio	3.73	18.46	20.55	25.17
Price / Sales	1.99	282.12	547.77	71.22
Price / Cash	3.69	55.27	27.48	37.27
Price / Book	1.54	6.62	9.71	6.65
Net Income	$163.05M	$24.40M	$3.56B	$335.32M
7 Day Performance	3.33%	-2.83%	-1.77%	-1.75%
1 Month Performance	7.10%	-3.21%	-2.53%	-1.10%
1 Year Performance	-35.55%	58.03%	31.63%	28.42%

CorMedix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRMD CorMedix	3.2245 of 5 stars	$7.92 +4.8%	$15.00 +89.5%	-38.5%	$623.29M	$311.71M	3.73	30	Earnings Report Analyst Revision
HCM HUTCHMED	3.9891 of 5 stars	$12.87 -2.0%	$16.88 +31.1%	-6.6%	$2.24B	$548.51M	N/A	1,796
ZLAB Zai Lab	3.9417 of 5 stars	$19.59 +5.3%	$45.83 +134.0%	-33.4%	$2.22B	$453.28M	N/A	1,784	Analyst Downgrade Insider Trade Gap Down
ADPT Adaptive Biotechnologies	3.5036 of 5 stars	$13.54 -2.0%	$20.00 +47.7%	+41.8%	$2.17B	$295.41M	N/A	790
TRVI Trevi Therapeutics	3.3761 of 5 stars	$14.88 +2.6%	$22.90 +53.9%	+118.5%	$2.11B	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRMD) was last updated on 5/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CorMedix (CRMD) Competitors

CRMD vs. HCM, ZLAB, ADPT, TRVI, and SION

How does CorMedix compare to HUTCHMED?

Summary

How does CorMedix compare to Zai Lab?

Summary

How does CorMedix compare to Adaptive Biotechnologies?

Summary

How does CorMedix compare to Trevi Therapeutics?

Summary

How does CorMedix compare to Sionna Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRMD vs. The Competition

CorMedix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CorMedix (CRMD) Competitors

CRMD vs. HCM, ZLAB, ADPT, TRVI, and SION

How does CorMedix compare to HUTCHMED?

Do analysts prefer HCM or CRMD?

Is HCM or CRMD more profitable?

Which has better earnings and valuation, HCM or CRMD?

Do insiders & institutionals believe in HCM or CRMD?

Which has more volatility & risk, HCM or CRMD?

Does the media prefer HCM or CRMD?

Summary

How does CorMedix compare to Zai Lab?

Do analysts prefer CRMD or ZLAB?

Which has better earnings & valuation, CRMD or ZLAB?

Does the media refer more to CRMD or ZLAB?

Which has more risk & volatility, CRMD or ZLAB?

Do insiders & institutionals believe in CRMD or ZLAB?

Is CRMD or ZLAB more profitable?

Summary

How does CorMedix compare to Adaptive Biotechnologies?

Is ADPT or CRMD more profitable?

Do analysts rate ADPT or CRMD?

Which has more volatility and risk, ADPT or CRMD?

Does the media prefer ADPT or CRMD?

Which has stronger earnings and valuation, ADPT or CRMD?

Do institutionals & insiders believe in ADPT or CRMD?

Summary

How does CorMedix compare to Trevi Therapeutics?

Is CRMD or TRVI more profitable?

Do analysts prefer CRMD or TRVI?

Do insiders & institutionals believe in CRMD or TRVI?

Which has stronger earnings & valuation, CRMD or TRVI?

Does the media favor CRMD or TRVI?

Which has more volatility & risk, CRMD or TRVI?

Summary

How does CorMedix compare to Sionna Therapeutics?

Do institutionals and insiders hold more shares of CRMD or SION?

Is CRMD or SION more profitable?

Do analysts recommend CRMD or SION?

Which has preferable valuation and earnings, CRMD or SION?

Which has more risk & volatility, CRMD or SION?

Does the media favor CRMD or SION?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRMD vs. The Competition

CorMedix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools